Now showing items 1-3 of 3

Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases

Reyes, César; Molina Franky, Jessica S.; Aza Conde, Jorge; Suárez, Carlos F.; Pabón, Laura; Moreno Vranich, Armando; Patarroyo, Manuel A.; Patarroyo, Manuel Elkin (2020)

Malaria remains a large-scale public health problem, killing more than 400,000 people and infecting up to 230 million worldwide, every year. Unfortunately, despite numerous efforts and research concerning vaccine development, ...
SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population

Patarroyo, Manuel-Alfonso; Patarroyo, Manuel-Elkin; Pabón, Laura; Alba, Martha patricia; Bermudez, Adriana; Rugeles, María Teresa; Diaz-Arevalo, Diana; Zapata, Wildeman; Zapata, María Isabel; Reyes, César; Suarez, Carlos F.; Agudelo, William (2022)

Fifty ~20–amino acid (aa)–long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus’ main genetic variants ...
Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans

Suárez, Carlos F.; Pabón, Laura; Barrera, Ana; Aza Conde, Jorge; Patarroyo, Manuel Alfonso; Patarroyo, Manuel Elkin (2017)

More than 50 years ago the owl monkey (genusAotus) was found to be highly susceptible to developinghuman malaria, making it an excellent experimental model for this disease. Microbes and parasites'(especially malaria) ...

Envíos recientes

Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases
...
Reyes, César | 2020

Malaria remains a large-scale public health problem, killing more than 400,000 people and infecting up to 230 million worldwide, every year. Unfortunately, despite numerous efforts and research concerning vaccine development, results to date have been low and/or strain-specific. This work describes a strategy involving Plasmodium falciparum Duffy binding-like (DBL) and reticulocyte-binding protein homologue (RH) family-derived minimum functional peptides, netMHCIIpan3.2 parental and modified peptides’ in silico binding prediction and modeling some Aotus major histocompatibility class II (MHCII) molecules based on known human molecules’ structure to understand their differences. These are used to explain peptides’ immunological behaviour when used as vaccine components in the Aotus model. Despite the great similarity between human and Aotus immune system molecules, around 50% of Aotus allele molecules lack a counterpart in the human immune system which could lead to an Aotus-specific vaccine. It was also confirmed that functional Plasmodium falciparum’ conserved proteins are immunologically silent (in both the animal model and in-silico prediction); they must therefore be modified to elicit an appropriate immune response. Some peptides studied here had the desired behaviour and can thus be considered components of a fully-protective antimalarial vaccine.

LEER
SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population
...
Patarroyo, Manuel-Alfonso | 2022

Fifty ~20–amino acid (aa)–long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus’ main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPIIL) formation, replacing β-branched, aromatic aa, short-chain backbone H-bond-forming residues, π-π interactions (n→π* and π-CH), aa interaction with π systems, and molecular fragments able to interact with them, disrupting PPIIL propensity formation. All these modified structures had PPIIL formation propensity to enable target peptide interaction with human leukocyte antigen-DRβ1* (HLA-DRβ1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DRβ1* molecules), predicted to cover 77.5% to 83.1% of the world’s population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development.

LEER
Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans
...
Suárez, Carlos F. | 2017

More than 50 years ago the owl monkey (genusAotus) was found to be highly susceptible to developinghuman malaria, making it an excellent experimental model for this disease. Microbes and parasites'(especially malaria) tremendous genetic variability became resolved during our malaria vaccine devel-opment, involving conserved peptides having high host cell binding activity (cHABPs); however, cHABPsare immunologically silent and must be specially modified (mHABPs) to induce a perfectfit into majorhistocompatibility complex (MHC) molecules (HLA in humans). Since malarial immunity is mainlyantibody-mediated and controlled by the HLA-DRB genetic region, ~1000Aotushave been molecularlycharacterised for MHC-DRB, revealing striking similarity between human andAotusMHC-DRB reper-tories. Such convergence suggested that a large group of immune protection-inducing protein structures(IMPIPS), highly immunogenic and protection inducers against malarial intravenous challenge inAotus,could easily be used in humans for inducing full protection against malaria. We highlight the value of alogical and rational methodology for developing a vaccine in an appropriate animal model:Aotusmonkeys

LEER

‹›

Browsing by Author "Pabón, Laura"

Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases ﻿

SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population ﻿

Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans ﻿

Envíos recientes

Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases

SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population

Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans

Malaria: Paving the way to developing peptide-based vaccines against invasion in infectious diseases

SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s Population

Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans